Skip header and navigation

Refine By

774 records – page 1 of 78.

A 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: Update of safety and quality-of-life findings.

https://arctichealth.org/en/permalink/ahliterature80782
Source
J Br Menopause Soc. 2006 Sep;12(3):115-25
Publication Type
Article
Date
Sep-2006
Author
Heikkinen Jorma
Vaheri Raija
Timonen Ulla
Author Affiliation
The Deaconness Institute of Oulu, Isokatu, Oulu, Finland.
Source
J Br Menopause Soc. 2006 Sep;12(3):115-25
Date
Sep-2006
Language
English
Publication Type
Article
Keywords
Breast Neoplasms - chemically induced - epidemiology
Cerebrovascular Accident - chemically induced - epidemiology
Dose-Response Relationship, Drug
Endometrial Neoplasms - chemically induced - epidemiology
Estradiol - administration & dosage - adverse effects - analogs & derivatives
Estrogens, Conjugated (USP) - administration & dosage - adverse effects
Female
Finland
Follow-Up Studies
Hormone Replacement Therapy - adverse effects - psychology
Humans
Medroxyprogesterone 17-Acetate - administration & dosage - adverse effects
Middle Aged
Postmenopause - drug effects - physiology
Quality of Life
Treatment Outcome
Abstract
OBJECTIVE: To assess the safety and health-related quality of life (HRQOL) of continuous combined hormone replacement therapy (ccHRT) with estradiol valerate/medroxyprogesterone acetate (E(2)V/MPA) over nine years and at follow-up one year after discontinuation. Study design: A total of 419 women were randomized to one of four treatments: once-daily 1 mg E2V/2.5 mg MPA (1 + 2.5 group); 1 mg E2V/5 mg MPA daily (1 + 5 group); 2 mg E2V/2.5 mg MPA daily (2 + 2.5 group); 2 mg E2V/5 mg MPA daily (2 + 5 group) (Indivina, Orion Pharma). For the last six months, all received the 1 + 2.5 dosage. The 2 + 2.5 dosage was discontinued at the end of year 7. A total of 198 women continued after year 7. RESULTS: Annualized percentage rates for cardiovascular events [corrected] and endometrial cancers [corrected] were below national rates for Finland and those reported for the Women's Health Initiative. There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation. Climacteric symptoms remained significantly below baseline values after dosage reduction; some symptoms recurred after discontinuation of ccHRT. HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest. Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9. They deteriorated during follow-up in women not continuing ccHRT. CONCLUSIONS: Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns. Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up. This supports the need for an individualized approach to therapy recommendations.
Notes
Erratum In: J Br Menopause Soc. 2006 Dec;12(4):174
PubMed ID
16953985 View in PubMed
Less detail

The 2002 Canadian bone densitometry recommendations: take-home messages.

https://arctichealth.org/en/permalink/ahliterature187804
Source
CMAJ. 2002 Nov 12;167(10):1141-5
Publication Type
Article
Date
Nov-12-2002
Author
Aliya A Khan
Jacques P Brown
David L Kendler
William D Leslie
Brian C Lentle
E Michael Lewiecki
Paul D Miller
R Lawrence Nicholson
Wojciech P Olszynski
Nelson B Watts
Author Affiliation
Division of Geriatrics, McMaster University, Hamilton, ON. Avkhan@aol.com
Source
CMAJ. 2002 Nov 12;167(10):1141-5
Date
Nov-12-2002
Language
English
Publication Type
Article
Keywords
Bone Density
Canada
Female
Hip
Humans
Lumbar Vertebrae
Middle Aged
Osteoporosis, Postmenopausal - diagnosis
Practice Guidelines as Topic
Risk factors
Notes
Cites: Arch Intern Med. 1997 Dec 8-22;157(22):2609-159531230
Cites: Calcif Tissue Int. 1997 Dec;61(6):433-409383266
Cites: J Bone Miner Res. 1998 Oct;13(10):1587-939783547
Cites: Osteoporos Int. 1998;8 Suppl 4:S7-8010197173
Cites: JAMA. 1999 Aug 18;282(7):637-4510517716
Cites: Osteoporos Int. 1997;7 Suppl 3:S108-169536315
Cites: Osteoporos Int. 2000;11(3):192-20210824234
Cites: Am J Med. 2000 Sep;109(4):267-7610996576
Cites: J Bone Miner Res. 2000 Oct;15(10):1867-7011028437
Cites: Osteoporos Int. 2001;12(1):49-5411305083
Cites: Osteoporos Int. 2001;12(7):519-2811527048
Cites: J Clin Densitom. 2002 Fall;5(3):247-5712357062
Cites: CMAJ. 2002 Nov 12;167(10 Suppl):S1-3412427685
Cites: Ann Intern Med. 1991 Jun 1;114(11):919-232024857
Cites: J Bone Miner Res. 1992 Jun;7(6):639-461414482
Cites: Am J Epidemiol. 1993 May 1;137(9):1001-58317445
Cites: J Bone Miner Res. 1993 Oct;8(10):1227-338256660
Cites: J Bone Miner Res. 1994 Jun;9(6):951-608079669
Cites: World Health Organ Tech Rep Ser. 1994;843:1-1297941614
Cites: Osteoporos Int. 1994 Jul;4(4):226-97949753
Cites: N Engl J Med. 1995 Mar 23;332(12):767-737862179
Cites: J Orthop Res. 1995 Mar;13(2):250-77722762
Cites: Bone. 1995 Apr;16(4 Suppl):257S-262S7626313
Cites: Osteoporos Int. 1995;5(4):262-707492865
Cites: N Engl J Med. 1995 Nov 30;333(22):1437-437477143
Cites: BMJ. 1996 May 18;312(7041):1254-98634613
Cites: Bone. 1996 Mar;18(3 Suppl):197S-201S8777088
Cites: Lancet. 1996 Aug 24;348(9026):511-48757153
Cites: N Engl J Med. 1997 Sep 4;337(10):670-69278463
Comment In: CMAJ. 2003 Jan 21;168(2):14912538531
PubMed ID
12427706 View in PubMed
Less detail

Abnormal cervical cytology is associated with increased nitric oxide release in the uterine cervix.

https://arctichealth.org/en/permalink/ahliterature89757
Source
Acta Obstet Gynecol Scand. 2009;88(4):417-21
Publication Type
Article
Date
2009
Author
Rahkola Paivi
Mikkola Tomi S
Nieminen Pekka
Ylikorkala Olavi
Vaisanen-Tommiska Mervi
Author Affiliation
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland.
Source
Acta Obstet Gynecol Scand. 2009;88(4):417-21
Date
2009
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Body Fluids - metabolism
Cervix Uteri - cytology - metabolism
Contraceptives, Oral - administration & dosage - adverse effects
Female
Humans
Menstrual Cycle - physiology
Middle Aged
Nitric Oxide - analysis - metabolism
Papillomavirus Infections - metabolism - pathology
Postmenopause
Sweden
Uterine Cervical Dysplasia - metabolism - pathology - virology
Vaginal Smears
Young Adult
Abstract
OBJECTIVE: The human uterine cervix is capable of producing nitric oxide (NO). We studied the impact of cytological changes on the release of cervical NO. DESIGN: Population-based case-control study. SETTING: City of Helsinki, Finland. POPULATION: Cervical cytology tests and cervical fluid samples were collected in 297 women. METHODS: Cervical cytology tests, classified according to Bethesda criteria, were specifically analyzed for changes typically seen in human papillomavirus (HPV) infection, and the level of NO metabolites (NOx) in cervical fluid was assessed by Griess reaction. MAIN OUTCOME MEASURES: The difference in cervical fluid NOx between normal and abnormal cytology. RESULTS: Cervical cytology was normal in 219 women and abnormal in 78 women. Among women with abnormal cytology there was both a higher detection rate (89% vs. 71%) and a higher concentration of NOx (median 22.5 micromol/l, 95% CI 14.6-31.9 vs. 11.0 micromol/l, 95% CI 8.0-16.7) compared to women with normal cytology. Age, parity, use of oral contraceptives, phase of the menstrual cycle, or history of miscarriage or termination of early pregnancy were not linked to an increased cervical NOx level. CONCLUSIONS: Cervical cell changes (suggestive of HPV infection) are accompanied by an increased release of NO in the human cervix. The significance of this finding remains uncertain, but in theory, increased release of NO could modify the outcome of cervical infection.
PubMed ID
19266358 View in PubMed
Less detail

Access to osteoporosis treatment is critically linked to access to dual-energy x-ray absorptiometry testing.

https://arctichealth.org/en/permalink/ahliterature161794
Source
Med Care. 2007 Sep;45(9):896-901
Publication Type
Article
Date
Sep-2007
Author
Suzanne M Cadarette
Monique A M Gignac
Susan B Jaglal
Dorcas E Beaton
Gillian A Hawker
Author Affiliation
Osteoporosis Research Program, Women's College Hospital, University of Toronto, Ontario, Canada. s.cadarette@utoronto.ca
Source
Med Care. 2007 Sep;45(9):896-901
Date
Sep-2007
Language
English
Publication Type
Article
Keywords
Absorptiometry, Photon - utilization
Aged
Aged, 80 and over
Cohort Studies
Female
Health Services Accessibility - statistics & numerical data
Humans
Mass Screening - utilization
Ontario - epidemiology
Osteoporosis, Postmenopausal - diagnosis - epidemiology - prevention & control
Professional-Patient Relations
Quality Assurance, Health Care - statistics & numerical data
Questionnaires
Referral and Consultation - statistics & numerical data
Reproducibility of Results
Risk assessment
Women's health
Abstract
To determine if inequities in access to osteoporosis investigation [dual-energy x-ray absorptiometry (DXA) testing] and treatment (bisphosphonate, calcitonin, and/or raloxifene) exist among older women in a region with universal health care coverage.
Community-dwelling women aged 65-89 years residing within 2 regions of Ontario, Canada were randomly sampled. Data were collected by standardized telephone interview. Potential correlates of DXA testing (verified by physician records), and current treatment were grouped by type as: "predisposing characteristics," "enabling resources," or "need factors" based on hypothesized relationships formulated before data collection. Variables associated with each outcome independent of "need factors" identified inequities in the system.
Of the 871 participants (72% response rate), 55% had been tested by DXA and 20% were receiving treatment. Using multiple variable logistic regression to adjust for need factors, significant inequities in access to DXA testing existed by age, health beliefs, education, income, use of preventive health services, region, and provider sex. DXA testing mediated access to treatment; 34% of those having had a DXA were treated compared with 2% of those who did not. Among women with osteoporosis, correctly reporting that their DXA test indicated osteoporosis and higher perceived benefits of taking pharmacological agents for osteoporosis were associated with treatment.
Significant inequities in access to fracture prevention exist in a region with universal health care coverage. Improved access to DXA and better communication to patients of both their DXA results and the benefits of treatment has the potential to reduce the burden of osteoporosis.
PubMed ID
17712261 View in PubMed
Less detail

[A cross-sectional study of lipid metabolism in postmenopausal women]

https://arctichealth.org/en/permalink/ahliterature93656
Source
Kardiologiia. 2007;47(6):37-40
Publication Type
Article
Date
2007
Author
Izmozherova N V
Popov A A
Andreev A N
Source
Kardiologiia. 2007;47(6):37-40
Date
2007
Language
Russian
Publication Type
Article
Keywords
Adult
Cross-Sectional Studies
Dyslipidemias - blood - epidemiology
Female
Humans
Lipid Metabolism - physiology
Lipids - blood
Middle Aged
Postmenopause - blood
Prevalence
Risk factors
Siberia - epidemiology
Urban Population
Abstract
AIM: To assess frequency of atherogenic dyslipidemia in postmenopausal residents of Ekateringurg. METHODS: Cross-sectional study included 1100 female patients of outpatient menopausal clinic. All were residents of Ekaterinburg aged from 28 to 64 years. The participants of the study were divided into 3 groups; the 1st group consisted of women younger than 45 years, the 2nd group included persons aged between 45 and 54 years, in the 3rd group comprized patients aged from 55 to 64 years. RESULTS: Normal lipid metabolism parameters were found in 18% of women. Most frequent dyslipidemias were 2A (44%) and 2B (26%) types. Frequencies of stable angina on exertion, transitory cerebral ischemic attacks, and myocardial infarction increased after the age of 45 years. CONCLUSION: More than 80% of symptomatic postmenopausal women had atherogenic dyslipidemias. The percentage of postmenopausal women who had indication for lipid lowering therapy was high.
PubMed ID
18260873 View in PubMed
Less detail

Acrylamide exposure and incidence of breast cancer among postmenopausal women in the Danish Diet, Cancer and Health Study.

https://arctichealth.org/en/permalink/ahliterature93773
Source
Int J Cancer. 2008 May 1;122(9):2094-100
Publication Type
Article
Date
May-1-2008
Author
Olesen Pelle Thonning
Olsen Anja
Frandsen Henrik
Frederiksen Kirsten
Overvad Kim
Tjønneland Anne
Author Affiliation
National Food Institute, Technical University of Denmark, Søborg, Denmark. petol@food.dtu.dk
Source
Int J Cancer. 2008 May 1;122(9):2094-100
Date
May-1-2008
Language
English
Publication Type
Article
Keywords
Acrylamide - adverse effects
Aged
Biological Markers - blood
Breast Neoplasms - blood - epidemiology - etiology
Case-Control Studies
Cohort Studies
Denmark - epidemiology
Environmental Exposure - adverse effects
Epoxy Compounds - blood
Female
Hemoglobins - metabolism
Humans
Incidence
Medical Record Linkage
Middle Aged
Odds Ratio
Postmenopause
Prospective Studies
Registries
Risk factors
Smoking - adverse effects
Abstract
Acrylamide, a probable human carcinogen, is formed in several foods during high-temperature processing. So far, epidemiological studies have not shown any association between human cancer risk and dietary exposure to acrylamide. The purpose of this study was to conduct a nested case control study within a prospective cohort study on the association between breast cancer and exposure to acrylamide using biomarkers. N-terminal hemoglobin adduct levels of acrylamide and its genotoxic metabolite, glycidamide in red blood cells were analyzed (by LC/MS/MS) as biomarkers of exposure on 374 breast cancer cases and 374 controls from a cohort of postmenopausal women. The adduct levels of acrylamide and glycidamide were similar in cases and controls, with smokers having much higher levels (approximately 3 times) than nonsmokers. No association was seen between acrylamide-hemoglobin levels and breast cancer risk neither unadjusted nor adjusted for the potential confounders HRT duration, parity, BMI, alcohol intake and education. After adjustment for smoking behavior, however, a positive association was seen between acrylamide-hemoglobin levels and estrogen receptor positive breast cancer with an estimated incidence rate ratio (95% CI) of 2.7 (1.1-6.6) per 10-fold increase in acrylamide-hemoglobin level. A weak association between glycidamide hemoglobin levels and incidence of estrogen receptor positive breast cancer was also found, this association, however, entirely disappeared when acrylamide and glycidamide hemoglobin levels were mutually adjusted.
PubMed ID
18183576 View in PubMed
Less detail

The acupuncture treatment for postmenopausal hot flushes (Acuflash) study: traditional Chinese medicine diagnoses and acupuncture points used, and their relation to the treatment response.

https://arctichealth.org/en/permalink/ahliterature148685
Source
Acupunct Med. 2009 Sep;27(3):101-8
Publication Type
Article
Date
Sep-2009
Author
Einar Kristian Borud
Terje Alræk
Adrian White
Sameline Grimsgaard
Author Affiliation
The National Research Center in Complementary and Alternative Medicine, University of Tromsø, N-9037 Tromsø, Norway. einar.borud@uit.no
Source
Acupunct Med. 2009 Sep;27(3):101-8
Date
Sep-2009
Language
English
Publication Type
Article
Keywords
Acupuncture Therapy - methods
Combined Modality Therapy
Female
Health status
Hot Flashes - therapy
Humans
Middle Aged
Norway
Patient satisfaction
Postmenopause
Quality of Life
Research Design
Self Care - methods
Treatment Outcome
Women's health
Abstract
the multicentre, pragmatic, randomised controlled Acuflash study evaluated the effect of traditional Chinese medicine (TCM) acupuncture on postmenopausal vasomotor symptoms and health-related quality of life. It concluded that use of acupuncture in addition to self-care can contribute to a clinically relevant reduction of hot flushes and increased health-related quality of life. This article reports on the TCM syndrome diagnoses and acupuncture points used and their relation to the treatment response, and on treatment reactions and adverse events.
the acupuncture group (n = 134) received 10 acupuncture treatment sessions and advice on self-care; the control group (n = 133) received advice on self-care only. The study acupuncturists met the current membership criteria of the Norwegian Acupuncture Society, and had at least 3 years' experience of practising TCM acupuncture. They were free to diagnose and select acupuncture points for each participant, after initial discussion.
fifty per cent of the participants in the acupuncture group were diagnosed with Kidney Yin Xu as their primary TCM syndrome diagnosis. No statistically significant differences were demonstrated between the syndrome groups regarding the distribution of responders and non-responders, nor regarding the change in health-related quality of life scores. A core of common acupuncture points (SP6, HT6, KI7, KI6, CV4, LU7, LI4, and LR3) were used in all the syndromes, and in addition multiple idiosyncratic points. Core point selection and frequency of use did not differ between responders and non-responders. No serious adverse events were reported.
factors other than the TCM syndrome diagnoses and the point selection may be of importance regarding the outcome of the treatment.
PubMed ID
19734379 View in PubMed
Less detail

Acute effect of estrogen on metabolic coronary vasodilator responses to atrial pacing in postmenopausal women.

https://arctichealth.org/en/permalink/ahliterature205030
Source
Am J Cardiol. 1998 Jul 15;82(2):236-9
Publication Type
Article
Date
Jul-15-1998
Author
T J Anderson
Author Affiliation
Department of Medicine, University of Calgary, Alberta, Canada.
Source
Am J Cardiol. 1998 Jul 15;82(2):236-9
Date
Jul-15-1998
Language
English
Publication Type
Article
Keywords
Aged
Alberta
Coronary Disease - complications - physiopathology
Estrogen Replacement Therapy
Estrogens, Conjugated (USP) - therapeutic use
Female
Humans
Male
Middle Aged
Postmenopause
Vasodilation - drug effects
Women's health
Abstract
This study assessed the acute effect of intravenous conjugated equine estrogen on metabolic coronary vasodilation to atrial pacing in 22 postmenopausal women with coronary disease or risk factors for atherosclerosis. Impaired metabolic coronary vasodilation is present in postmenopausal women with atherosclerosis or its risk factors and is not acutely augmented by the intravenous administration of Premarin.
PubMed ID
9678297 View in PubMed
Less detail

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.

https://arctichealth.org/en/permalink/ahliterature140933
Source
Osteoporos Int. 2011 Jun;22(6):1725-35
Publication Type
Article
Date
Jun-2011
Author
D L Kendler
M R McClung
N. Freemantle
M. Lillestol
A H Moffett
J. Borenstein
S. Satram-Hoang
Y-C Yang
P. Kaur
D. Macarios
S. Siddhanti
Author Affiliation
University of British Columbia, 600-1285 West Broadway, V6H 3X8 Vancouver, BC, Canada. kendler@ca.inter.net
Source
Osteoporos Int. 2011 Jun;22(6):1725-35
Date
Jun-2011
Language
English
Publication Type
Article
Keywords
Administration, Oral
Aged
Alendronate - administration & dosage - adverse effects - therapeutic use
Antibodies, Monoclonal - administration & dosage - adverse effects - therapeutic use
Antibodies, Monoclonal, Humanized
Bone Density - drug effects
Bone Density Conservation Agents - administration & dosage - adverse effects - therapeutic use
British Columbia
Epidemiologic Methods
Female
Humans
Injections, Subcutaneous
Medication Adherence - statistics & numerical data
Middle Aged
Osteoporosis, Postmenopausal - drug therapy - physiopathology - psychology
Patient Preference - statistics & numerical data
Patient Satisfaction - statistics & numerical data
Treatment Outcome
Abstract
In this study, 250 women with osteoporosis were randomized to 12 months with subcutaneous denosumab 60 mg every 6 months or oral alendronate 70 mg once weekly, then crossed over to the other treatment. The primary endpoint, treatment adherence at 12 months, was 76.6% for alendronate and 87.3% for denosumab.
The purpose of this study is to evaluate treatment adherence with subcutaneous denosumab 60 mg every 6 months or oral alendronate 70 mg once weekly.
In this multicenter, randomized, open-label, 2-year, crossover study, 250 postmenopausal women with low bone mineral density received denosumab or alendronate for 12 months, then the other treatment for 12 months. The alendronate bottle had a medication event monitoring system cap to monitor administration dates. Definitions were as follows: compliance, receiving both denosumab doses 6 (± 1) months apart or 80-100% of alendronate doses; persistence, receiving both denosumab doses and completing the month 12 visit within the visit window or = 2 alendronate doses in the final month; adherence, achieving both compliance and persistence. This report includes data from the first 12 months.
The primary study endpoint, adherence in the first 12 months, was 76.6% (95/124) for alendronate and 87.3% (110/126) for denosumab. Risk ratios for denosumab compared with alendronate at 12 months were 0.58 (p = 0.043) for non-adherence, 0.48 (p = 0.014) for non-compliance, and 0.54 (p = 0.049) for non-persistence. Subject ratings for treatment necessity, preference, and satisfaction were significantly greater for denosumab and ratings for treatment bother were significantly greater for alendronate. Adverse events were reported by 64.1% of alendronate-treated subjects and 72.0% of denosumab-treated subjects (p = 0.403). The most common adverse events were arthralgia, back pain, pain in extremity, cough, and headache (each in
PubMed ID
20827547 View in PubMed
Less detail

774 records – page 1 of 78.